Stella Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2019 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2019 - 2020
Net Income	-137	-760	-775	-764	-656	Upgrade
Depreciation & Amortization	34	35	35	34	31	Upgrade
Other Operating Activities	-2	-1	-2	-	-4	Upgrade
Change in Accounts Receivable	-638	-16	-42	38	-55	Upgrade
Change in Inventory	-114	-175	-166	-380	-87	Upgrade
Change in Accounts Payable	-88	26	108	-13	38	Upgrade
Change in Other Net Operating Assets	1,085	15	15	4	-39	Upgrade
Operating Cash Flow	140	-876	-827	-1,081	-772	Upgrade
Capital Expenditures	-4	-10	-26	-46	-21	Upgrade
Sale (Purchase) of Intangibles	-8	-	-3	-	-1	Upgrade
Investment in Securities	300	-	-	-304	-	Upgrade
Other Investing Activities	-1	1	-	-	-	Upgrade
Investing Cash Flow	287	-9	-29	-350	-22	Upgrade
Long-Term Debt Issued	730	-	-	-	-	Upgrade
Long-Term Debt Repaid	-946	-160	-160	-160	-160	Upgrade
Net Debt Issued (Repaid)	-216	-160	-160	-160	-160	Upgrade
Issuance of Common Stock	941	388	451	3,616	199	Upgrade
Other Financing Activities	-4	-	-	373	-371	Upgrade
Financing Cash Flow	721	228	291	3,829	-332	Upgrade
Miscellaneous Cash Flow Adjustments	1	-	-	-1	-2	Upgrade
Net Cash Flow	1,149	-657	-565	2,397	-1,128	Upgrade
Free Cash Flow	136	-886	-853	-1,127	-793	Upgrade
Free Cash Flow Margin	14.15%	-329.37%	-372.49%	-1127.00%	-386.83%	Upgrade
Free Cash Flow Per Share	4.07	-28.60	-29.54	-40.13	-39.58	Upgrade
Cash Interest Paid	4	2	2	3	3	Upgrade
Cash Income Tax Paid	2	2	3	-	4	Upgrade
Levered Free Cash Flow	-859.75	-612.25	-569	-828	-571.5	Upgrade
Unlevered Free Cash Flow	-857.25	-611	-567.75	-826.13	-569.63	Upgrade
Change in Working Capital	245	-150	-85	-351	-143	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.